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A B S T R A C T
Objectives. We determined rates of
prenatal HIV testing and investigated
barriers to testing.
Methods. We surveyed 1362 repre-
sentative parturient women from 7 hos-
pitals in 4 locations of the United States.
Results. Overall, 89.9% of women
reported being offered HIV testing and
69.6% reported being tested. Propor-
tions of women not offered testing dif-
fered by location (range=5.2%–16.3%),
as did proportions not tested (range =
12.2%–54.4%).Among women who per-
ceived that their clinicians had not rec-
ommended testing, 41.7% were tested,
compared with 92.8% of women who
perceived a strong recommendation (P<
.05). Private insurance for prenatal care
was also associated with not being tested.
Women gave multiple reasons for not
being tested, most commonly not being
at risk, having been tested recently, and
the test’s not being offered or recom-
mended, cited by 55.3%, 39.1% and
11.1% of women, respectively.
Conclusions. Although most par-
turient women were offered a prenatal
HIV test and got tested, testing propor-
tions did not reach national goals and
differed significantly by location and
payment status. Concern about testing
consequences was not a major barrier.
Perception of clinicians’ recommenda-
tions strongly influenced testing. Chang-
ing provider practices will be essential
to implementing universal prenatal HIV
testing. (Am J Public Health. 2001;91:
727–733)
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Worldwide each year, an estimated 2.3
million children are exposed perinatally to
HIV, 6000 to 7000 of them in the United
States.1 Effective interventions such as the
use of antiretroviral medications, obstetric
practices that minimize exposure to maternal
bodily fluids, and formula feeding can now
dramatically reduce mother-to-child trans-
mission.2–11 Furthermore, treatment can pro-
long the lives of HIV-infected people. Most
interventions to prevent perinatal HIV trans-
mission require that women obtain prenatal
care, that clinicians offer testing, that women
accept testing, and that HIV-infected women
adhere to treatment and other interventions—
a complex interplay of behaviors. In response
to the prevention opportunity afforded by an-
tiretroviral prophylaxis during the perinatal
period, the US Public Health Service issued
guidelines in 1995 for universal voluntary
prenatal HIV testing.12 Recently, the Institute
of Medicine recommended that universal pre-
natal testing become a routine component of
prenatal care, a recommendation supported
by the American College of Obstetricians
and Gynecologists and the American Acad-
emy of Pediatrics.13,14
To determine the extent to which the
guidelines and recommendations have been
implemented, and to identify barriers to im-
plementation, we surveyed a representative
sample of women delivering in 7 hospitals in
1997 in 4 locations of the United States. Most
previous studies of perinatal HIV testing were
limited to a single state, included mostly high-
risk patients in public prenatal care settings,
predated effective prophylaxis, and typically
conducted assessment before the delivery.15–18
By design, these studies excluded women with
private care and women with late or no prenatal
care, and they missed testing done late in the
prenatal period. This survey overcame some of
these limitations and provided results that re-
flect the recent experience of a broad segment
of pregnant women in the United States.
Methods
Study Population
The sample comprised women who gave
birth in 1997 at 7 hospitals in 4 states: North
Carolina, Connecticut, NewYork, and Florida.
All hospitals were teaching hospitals where
care was financed by a number of different
public and private sources. Four were in cen-
tral North Carolina: Durham Regional Hos-
pital (2785 deliveries in 1997) and Duke Med-
ical Center (2085 deliveries) in Durham,
University of North Carolina Hospitals (2075
deliveries) in Chapel Hill, and Wake Medical
Center (3350 deliveries) in Raleigh. The re-
maining 3 were Yale New Haven Hospital in
Connecticut (5200 deliveries), the University
Hospital of Brooklyn in NewYork (2300 de-
liveries), and Jackson Memorial Hospital in
Miami, Fla (6029 deliveries).
We designed selection procedures to ob-
tain a representative sample of approximately
200 parturient women per hospital. Proce-
dures were not designed to select a probabil-
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ity sample. Excluded were those women
whose infant died or who were too sick to in-
terview, who did not speak English, Spanish,
or Haitian Creole (the study languages), or
who were mentally incompetent. The study
protocol was approved by institutional review
boards at each site and by the Centers for Dis-
ease Control and Prevention. All participants
provided informed consent.
The average number of days spent inter-
viewing at each hospital was 54.4 (range=29–
65). On the basis of the average number of
births per day in each hospital and the number
of days we spent interviewing in each hospital,
we estimated that we interviewed on average
44.3% of the women whose deliveries had oc-
curred on the interview days (range=31.7%–
53.7%).The overall refusal proportion among
the women approached was 10.5%.At all sites,
floor nurses helped study staff determine eli-
gibility. In North Carolina, we used the deliv-
ery log to ascertain all births in the prior 24
hours (vaginal births) or 48 hours (cesarean
births).We approached by birth order all eligi-
ble women in each group. Between 11% and
18% of mothers were not approached because
only English-speaking interviewers were avail-
able. In New Haven, we used the delivery log
to identify and approach all eligible women
who had given birth in the previous 48 hours.
In Brooklyn, we approached every other woman
identified on the postpartum ward nurses’daily
log. In Miami, we approached every third room
containing postpartum women.
Data Collection
Using centrally trained interviewers and
a structured interview lasting approximately
10 minutes, we gathered information about
prenatal care, sociodemographic factors, and
HIV counseling and testing during prenatal
care and prepregnancy. To determine percep-
tion of the strength of the provider’s recom-
mendation of testing, we asked whether
women thought their prenatal care provider
wanted them to be tested for HIV not at all, a
little, some, much, or very much. We elicited
with open-ended questions reasons for not
being tested. Reasons were coded independ-
ently by 2 readers; 1 investigator resolved dis-
crepancies. We asked women about payment
for prenatal care and categorized sources into
a mutually exclusive hierarchy: public fi-
nancing for those with any public sources
(Medicaid, Medicaid-funded health mainte-
nance organization, Medicare, military or Vet-
erans Administration); private insurance for
those with private insurance financed by
themselves, their spouse, their employer, or
their spouse’s employer; self-financing for
those who paid out-of-pocket; or other. Source
of funding was further dichotomized into pri-
vate insurance and no private insurance, with




Relative proportions, or relative risks, and 95%
confidence intervalswerecomputedas themea-
sure of association for 2 primary outcomes—
not being offered a test and not being tested—
with being offered a test and being tested as the
respective comparison groups. Bivariate and
multivariateanalyses includedthefollowingfac-
tors: demographics (age, race/ethnicity, educa-
tion, marital status), economic information (an-
nual household income and source of payment
for prenatal care), trimester in which prenatal
care began, history of prepregnancy HIV test-
ing, women’s perception of the strength of the
provider’s recommendation,andlocation.North
Carolina was the reference location for reasons








A total of 1362 parturient women were in-
terviewed(753fromcentralNorthCarolina,208
from New Haven, 201 from Brooklyn, and 200
from Miami). Sociodemographic characteris-
tics differed substantially by location, with
womeninNorthCarolinaandNewHavenmore
likely tobeolder,White,andmarriedandtohave
higher incomes, private insurance, and earlier
entry into prenatal care (Table 1).At each loca-
tion, key sociodemographic characteristics of
thestudypopulationmatchedthoseofparturient
womenin1997ateachhospital (datanotshown).
Of the total sample, 57.6% had been tested
for HIV before the current pregnancy: 49.9%
during an earlier pregnancy and 23.4% within
6 months of the current pregnancy (53.7% had
been tested more than once). We excluded from
further analysis 3 Miami women who were
known to be HIV infected prior to pregnancy;
they were neither offered testing nor retested.
Prenatal Counseling and Offering of
Testing
Most women (88%) had received infor-
mation about HIV, AIDS, and HIV testing at
their prenatal clinic. The most common
sources for this information were an individ-
ual session with a health care provider (78%)
and written materials (56%).
Overall, 1192 women (89.9%; 95% con-
fidence interval [CI] = 88.1%, 91.5%) re-
ported being offered an HIV test during a
prenatal visit (Table 2), including 56 women
who had not received information about HIV/
AIDS at the prenatal clinic. Of the 134
women who said they were not offered an
HIV test, 74 reported receiving no informa-
tion on HIV/AIDS.
The proportions of women offered pre-
natal HIV testing differed by location. Com-
pared with women in North Carolina, sig-
nificantly more New Haven women were
not offered testing (Table 2). In a multivari-
ate model of not being offered testing that
included location, demographics, and
trimester in which prenatal care was initi-
ated, relative to North Carolina, the adjusted
odds ratio for not being offered a test was
elevated for New Haven (odds ratio [OR] =
1.9; 95% CI = 1.2, 3.1) and Miami (OR =
2.0; 95% CI = 1.1, 3.6). Also, older age
(OR = 1.2 per 5-year increment; 95% CI =
1.0, 1.4) and third-trimester initiation of pre-
natal care (OR=3.1; 95% CI=1.3, 7.6) were
significant independent factors associated
with not being offered a test, as were higher
educational attainment (OR=1.4; 95% CI=
0.9, 2.2) and private insurance (OR = 1.5;
95% CI=0.9, 2.4), albeit with marginal sta-
tistical significance.
Prenatal HIV Testing
Overall, 916 women (69.6%; 95% CI=
67.0%, 72.0%) reported getting an HIV test
during a prenatal care visit and 401 women
(30.4%; 95% CI=28.0%, 33.0%) did not. Of
all women tested, 56% had first-trimester tests,
33% second-trimester tests, and 11% third-
trimester tests. Of the 561 women who had
not been tested before, 66% got tested, ac-
counting for 41% of all women who got
tested. Of women not tested, 11 (6 from
Miami) were tested after entering the hospi-
tal for delivery.
Five women reported positive HIV test
results determined during pregnancy. How-
ever, none of the 5 indicated whether they had
had a prior HIV test. Thirty women who were
tested did not know their test results, includ-
ing 4 who had not returned for test results and
9 who had test results pending.
Factors Associated With Not Being
Tested
In addition to those known to be HIV se-
ropositive, those without prenatal care, and
those not offered a test, we also excluded from
the analysis 21 women whose testing status
was unknown. Of the remaining 1171 women,
23.7% were not tested. Testing proportions
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TABLE 2—Proportions of Women Offered HIV Testing and Tested During Prenatal Care and the Relation of Geographic
Location, Not Being Offered Testing, and Not Being Tested
Tested for HIV During Prenatal Care
Prenatal HIV Testing Offereda All Womenb Only Among Women Offered Testingc
Yes No Yes No Yes No
n % n % RR (95% CI) n % n % RR (95% CI) n % n % RR (95% CI)
Central North 672 90.8 68 9.2 1.0 494 67.8 235 32.2 1.0 483 73.4 175 26.6 1.0
Carolina
New Haven 170 83.7 33 16.3 1.8 (1.2, 2.6) 94 45.6 112 54.4 1.7 (1.4, 2.0) 91 54.2 77 45.8 1.7 (1.4, 2.1)
Brooklyn 182 94.8 10 5.2 0.6 (0.3, 1.1) 163 84.0 31 16.0 0.5 (0.4, 0.7) 160 89.9 18 10.1 0.4 (0.2, 0.6)
Miami 168 87.0 23 12.0 1.3 (0.8, 2.0) 165 87.8 23 12.2 0.4 (0.3, 0.6) 159 95.2 8 4.8 0.2 (0.1, 0.4)
All sites 1192 89.9 134 10.1 916 69.6 401 30.4 893 76.3 278 23.7
Note. RR=relative risk; CI=confidence interval. Central North Carolina (including Chapel Hill, Durham, and Raleigh) is the reference group for
the relative risk.
aExcluded 36 women: 3 known to be HIV seropositive prior to pregnancy, 22 who did not recall if they had been offered testing, and 11 for
whom answers were missing.
bExcluded 45 women: 3 known to be HIV seropositive prior to pregnancy, 37 who were unsure if they were tested, and 5 who did not answer
the question.
cExcluded 21 women: 18 who had been offered testing but were unsure if they were tested, 2 whose data on whether they were tested were
missing, and 1 who refused to answer.
TABLE 1—Social and Demographic Characteristics of Study Women
Central
All Sites, % North Carolina, % New Haven, % Brooklyn, % Miami, %
(n=1362) (n=753) (n=208) (n=201) (n=200)
Age, y (mean±SD) (27.4±6.4) (27.3±6.4) (29.3±5.9) (26.8±6.4) (26.8±6.5)
15–19 12.5 13.4 6.8** 12.9 15.6
20–29 47.6 48.2 40.1 50.3 49.8
≥30 40.0 38.3 53.1 36.8 34.7
Married 58.5 61.7 72.6* 40.8** 46.7**
Education≤high school 42.9 35.7 31.1 54.7** 70.2**‡
Hispanic ethnicity 12.4 2.1 12.6** 8.0** 54.8**‡
Racea
White 42.9 51.4 63.7** 1.5** 34.7**‡
Black 43.4 40.3 20.4 83.1 41.2
Mixed 7.0 4.0 4.0 9.0 19.6
Other 5.7 4.3 11.9 6.5 4.0
Annual household income, $
≤15000 37.0 25.2 23.7* 58.9** 76.0**†
15001–60000 45.5 52.6 45.5 39.1 23.4
>60000 17.5 22.2 30.8 2.0 0.6
Source of payment for prenatal care
Public 47.3 43.9 25.0** 64.0** 65.8**‡
Private insurance 46.2 53.5 73.5 28.5 8.5
Self 4.4 1.5 1.0 0.5 23.1
Other 2.1 1.1 0.5 7.0 2.5
Received prenatal care 99.3 99.7 100.0 99.0 97.0**
Trimester of first prenatal care visit
First 81.8 84.3 89.3 74.5** 71.1**
Second 15.3 13.7 10.2 20.9 21.6
Third 2.9 2.0 0.5 4.6 7.4
Prior HIV test 57.6 58.7 53.2 50.8* 65.3†
Within 6 mo of conception 23.4 24.0 14.7* 21.8 30.4
More than once 53.7 55.0 55.0 47.5 53.2
During a prior pregnancy 49.9 50.1 54.1 43.6 50.8
Note. Central North Carolina includes Chapel Hill, Durham, and Raleigh. Percentages may not sum to 100.0% owing to rounding. All P values
are from 2-tailed tests.
aRace characterization as Black, White, or mixed was selected by the woman being interviewed. Other included women who selected the
categories Native American and Alaskan Native, Asian and Pacific Islander, or other.
*P<.01 for each location compared with Central North Carolina; **P≤ .001 for each location compared with Central North Carolina; †P<.01 for
Brooklyn compared with Miami; ‡P≤ .001 for Brooklyn compared with Miami.
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TABLE 3—Association Between Perception of Provider’s Recommendation and Prenatal HIV Testing Among Women Offered
an HIV Test, and Comparison of Testing Proportions Among Women With Private Insurance vs Public Funding for
Prenatal Care
HIV Testing During Pregnancy 
Perceived Strength Private Insurance for Prenatal Care Public Funding for Prenatal Care
of Provider’s Tested Not Tested Tested Not Tested
Recommendation na %b n %c n %c RR (95% CI) n %c n %c RR (95% CI) RRd (95% CI)
Very strong 348 30.2 103 91.2 10 8.9 (Reference) 218 93.6 15 6.4 (Reference) 1.4 (0.6, 3.0)
Strong 195 16.9 60 76.9 18 23.1 2.6 (1.3, 5.3) 108 93.1 8 6.9 1.1 (0.5, 2.5) 3.3 (1.5, 7.5)
Somewhat strong 279 24.2 84 60.4 55 39.6 4.5 (2.4, 8.4) 116 84.7 21 15.3 2.4 (1.3, 4.5) 2.6 (1.7, 4.0)
A little strong 223 19.3 55 47.4 61 52.6 5.9 (3.2, 11.0) 85 80.2 21 19.8 3.1 (1.7, 5.7) 2.7 (1.7, 4.0)
Not at all strong 108 9.4 15 23.4 49 76.6 8.7 (4.7, 15.9) 30 68.2 14 31.8 4.9 (2.6, 9.5) 2.4 (1.5, 3.8)
Total 1153 100.0 317 62.2 193 37.8 557 87.6 79 12.4 3.0 (2.4, 3.9)
Note. Public funding for prenatal care includes 79 who paid out-of-pocket for care or had other financing. RR=relative risk; CI=confidence
interval.
aExcluded 209 women who were not offered test (n=136) or for whom data were missing on woman’s perception (n=18), test offering (n=34),
or testing (n=21).
bColumn percentages.
cRow percentages. Excluded were 7 women for whom data on source of funding for prenatal care were missing.
dRelative risk comparing proportions who were not tested according to financing of prenatal care (private insurance vs public funding) at each
level of perception of how much provider recommended testing.
differed significantly by location, with the
proportion not tested ranging from 4.8%
(Miami) to 45.8% (New Haven) (Table 2).
Women with private insurance were 3
times more likely not to get tested than
women with public funding (Table 3). Pos-
sessing private insurance was also associated
with the perception that the provider did not
recommend testing (P< .001).
Proportions of women who were tested
increased incrementally with increased per-
ception that the provider considered testing
to be important, regardless of funding source
(P trend < .05 for each source) (Table 3).
Among women who perceived that the pro-
vider wanted very much for them to be tested,
91.2% and 93.6% of those with private in-
surance and with public funding, respectively,
were tested. Within each of the other levels
of perceived provider recommendation, the
proportion of those with private insurance
who were not tested was at least twice as high
as the proportion of those with public funding
who were not tested, a statistically significant
difference.Among women who perceived that
the provider did not at all want them to be
tested, 23.4% and 68.2% of those with pri-
vate insurance and with public funding, re-
spectively, were tested.
In all but 1 location, the proportion of
untested women who had perceived that the
provider did not at all recommend that they be
tested was higher than the proportion of
untested women who had perceived some
level of recommendation by the provider
(Table 4). The measure of association ranged
from 2.0 in New Haven, where 21% of
women perceived that the provider had not
recommended testing, to 5.8 in Miami, where
2% had this perception. In Brooklyn, provider
recommendation was not associated with HIV
testing, although only 18 women were not
tested. In a multivariate analysis to predict the
perception that the provider had not recom-
mended testing, location and higher income
were significant predictors after adjustment
for sociodemographic factors (data not
shown). Compared with women in North Car-
olina, women in New Haven were twice as
likely to have this perception; women in
Miami were one third as likely.
Lengthof timesince the lastpriorHIVtest
wasassociatedwithnotbeingtestedduringpreg-
nancy; however, having a prior test itself was
not. Women who had been tested within 6
months before pregnancy were significantly
more likely not to be tested than women with a
longer interval. The magnitude of this associa-
tionwassimilar inall locations (rangeof relative
risk=1.5–1.8)but reachedstatisticalsignificance
onlyinNorthCarolinaandNewHaven(Table4).
Several sociodemographic factors were
associated with not being tested in North Car-
olina and in New Haven (Table 4). More of the
women in these locations who were not tested
were older, were married, had an annual house-
hold income greater than $15000, or had ed-
ucation beyond high school. Also, in North
Carolina those of White race/ethnicity and with
first-trimester initiation of prenatal care were
more likely not to be tested than other women.
In Brooklyn, no sociodemographic factor was
associated with testing. In Miami, only late ini-
tiation of prenatal care was associated with not
being tested. Six of the 8 women not tested ini-
tiated care after the first trimester.
Multivariate modeling was performed,
which confirmed that not being tested had an
independent association with study location,
private insurance status, perception of the
strength of the provider’s recommendation,
having been tested within 6 months before
pregnancy, older age, and being married
(Table 4). Even after adjustment for all other
factors, it was found that more women in
Brooklyn and Miami and fewer women in New
Haven got tested compared with women in
North Carolina.
Reasons for Not Being Tested
396 women who were not tested gave a
total of 515 reasons for not being tested. Few
women cited possible negative consequences,
such as being too worried, concerned, or scared
to be tested (6.6%), fear of discrimination
(1.8%), or testing’s being contrary to their be-
liefs (1.5%). The most common reason, men-
tioned by 55.3% of women, was having no per-
ceived need for the test, and the next most
common reason was having been tested before
this pregnancy (39.1%). Women raised other
explanations much less commonly: not hav-
ing been offered testing or perceiving that test-
ing was not recommended (11.1%); no partic-
ular reason (4.0%); partner had tested HIV
negative (3.0%); a scheduling problem (2.5%);
just did not think about getting it done (2.3%);
cost (1.0%); intended to but just did not get
tested (0.5%); and already knew she was HIV
seropositive (0.5%).
The reasons for not being tested differed
by location. North Carolina (203 women giv-
ing 305 reasons) and New Haven (110 women
giving 144 reasons) had responses as described
above. In Miami (25 women giving 31 rea-
sons) 48.0% of women said that testing was
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TABLE 4—Factors Associated With Not Getting an HIV Test When the Test Was Offered During Prenatal Care
Adjusted OR,
Central North Carolina New Haven Brooklyn Miami All Locations
No. RR (95% CI) No. RR (95% CI) No. RR (95% CI) No. RR (95% CI) (95% CI)
Woman perceived that provider 
did not recommend getting 
an HIV test
True 35/56 2.7 (2.1, 3.5) 26/35 2.0 (1.5, 2.7) 1/13 0.7 (0.1, 5.1) 1/4 5.8 (0.9, 36.4) 4.2 (2.5, 7.0)
False 137/593 1.0 48/128 1.0 17/163 1.0 7/161 1.0
Private insurance for prenatal care
Yes 127/346 2.4 (1.8, 3.2) 63/117 1.8 (1.2, 3.0) 9/47 2.8 (1.2, 6.6) 0/14 . . .a 1.9 (1.2, 3.1)
No 48/310 1.0 14/48 1.0 9/130 1.0 8/152
Timing of prior HIV test
≤6 months prior to pregnancy 38/88 1.8 (1.4, 2.4) 9/13 1.6 (1.0, 2.3) 3/19 1.7 (0.5, 5.2) 3/34 2.3 (0.6, 9.1) 3.8 (2.4, 5.9)
>6 months prior to pregnancy 133/552 1.0 68/153 1.0 15/157 1.0 5/129 1.0
Age, y
≥30 100/245 2.3 (1.8, 3.0) 49/86 1.6 (1.2, 2.3) 6/65 0.9 (0.3, 2.2) 4/57 2.3 (0.7, 7.2) 1.6 (1.1, 2.2)
<30 73/408 1.0 28/81 1.0 12/113 1.0 4/109 1.0
White
Yes 121/328 2.2 (1.7, 3.0) 45/99 1.0 (0.7, 1.4) 0/3 . . .b 0/57 0.2 (0.0, 1.4) 1.2 (0.8, 1.7)
No 54/326 1.0 29/63 1.0 18/175 8/109 1.0
>High school education
Yes 170/576 4.9 (2.1, 11.5) 72/145 2.3 (1.0, 5.1) 15/141 1.3 (0.4, 4.4) 3/107 0.5 (0.2, 1.5) 1.4 (0.9, 1.5)
No 5/82 1.0 5/23 1.0 3/37 1.0 5/60 1.0
Household income, $
>15000 150/470 2.6 (1.7, 3.9) 60/117 1.3 (0.9, 2.1) 8/72 1.2 (0.5, 2.8) 1/38 0.3 (0.0, 2.2) 0.9 (0.6, 1.5)
≤15000 1.0 16/42 1.0 10/103 1.0 7/107 1.0
Married
Yes 141/401 2.6 (1.9, 3.7) 62/119 1.7 (1.1, 2.7) 8/72 1.2 (0.5, 2.9) 6/78 2.0 (0.6, 6.7) 2.0 (1.2, 3.1)
No 34/255 1.0 15/49 1.0 10/106 1.0 2/88 1.0
Initiation of prenatal care
1st trimester 146/525 1.6 (1.0, 2.5) 64/142 1.0 (0.6, 1.7) 15/128 2.4 (0.6, 10.3) 2/116 0.1 (0.0, 0.6) 0.9 (0.5, 1.4)
2nd or 3rd trimester 18/103 1.0 9/20 1.0 2/43 1.0 6/46 1.0
New Havenc . . . . . . . . . . . . . . . . . . . . . . . . 1.8 (1.2, 2.8)
Brooklyn . . . . . . . . . . . . . . . . . . . . . . . . 0.5 (0.3, 0.9)
Miami . . . . . . . . . . . . . . . . . . . . . . . . 0.2 (0.1, 0.4)
Note. Central North Carolina includes Chapel Hill, Durham, and Raleigh. RR=unadjusted relative risk for not getting an HIV test during
pregnancy vs getting a test, comparing bivariate levels of each factor. OR=odds ratio derived from logistic regression model containing all
factors.
aRelative risk was undefined owing to zero cells. Chi-square P value was 0.323.
bRelative risk was undefined owing to zero cells. Chi-square P value was 0.56.
cReference group is Central North Carolina.
not offered or was not recommended. Another
20.0% mentioned having no perceived need
for testing. In Brooklyn (31 women giving 35
reasons) 35.5% mentioned having had a prior
test; 35.5% cited no particular reason; 19.4%
included feeling no need to be tested; and
12.9% stated that testing was not offered or not
recommended.
Discussion
HIV testing during pregnancy is a key
component of efforts to eliminate mother-to-
child HIV transmission. In this 1997 sample
of births in 7 hospitals in 4 states, almost 90%
of women were offered a prenatal HIV test,
and about 75% of those women offered were
tested. Although our data demonstrate that most
women were offered and chose testing, they
also indicate that nearly one third of women
overall gave birth unaware of their HIV status.
While some may consider these proportions
adequate, there was important variation within
and between locations, driven by differences
in health system factors such as private insur-
ance status and strength of provider recom-
mendation. Women rarely mentioned fear of
adverse consequences as the reason for not get-
ting tested. Thus, the recommendation by pub-
lic health and medical care leadership for uni-
versal testing,13 if implemented by prenatal
providers, would be likely to gain acceptance
by most women.
All 4 states had adopted the recommen-
dation of universal voluntary testing before the
study began, but only in Miami and Brooklyn
did HIV testing proportions reach 90%. In lo-
cations with lower testing proportions (North
Carolina and New Haven), demographic fac-
tors were associated with lack of testing, indi-
cating that prenatal HIV testing may have been
guided by notions of risk status identified by
women or their providers. Although HIV test-
ing has been associated with several demo-
graphic and clinic-level factors,16,20,21 we had
expected that this phenomenon would have
changed by 1997.
Health care providers’ recommendation
strongly influenced women’s decisions on pre-
natal testing, independently of other factors.
Among women who perceived that providers
stronglyrecommendedtesting,93%were tested,
a proportion 2.2 times greater than that among
women who perceived that providers did not
recommend testing. The perception of a rec-
ommendation to get tested was associated with
women’s location and younger age, indirect ev-
idence that theprovidersmayhavebeenassess-
ingHIVrisk.Althoughcliniciansvoicesupport
foruniversalprenatal testing, their clinicalprac-
tice often hinges on appraisal of women’s
risk,22,23 even though such appraisal has been
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shown to be inaccurate.24 Inexperience, dis-
comfort with discussing HIV, or lack of time
mayalso leadproviders to not recommend test-
ing strongly.25–28 Clinic policies also may affect
clinicians’practices.29 Finally, our finding that
morewomenwith late initiationofprenatal care
were not offered testing may indicate a barrier
related to competing clinical care priorities late
in pregnancy.
Private insurance for prenatal care was
associated with lack of testing after other fac-
tors were adjusted for, except in Miami, where
all 14 women with private insurance were
tested. Others have documented lower prena-
tal testing proportions among private prenatal
clinic patients.30 The 1999 Institute of Medicine
report provides specific recommendations for
changing the actions of prenatal care providers,
including increasing the public health and med-
ical communities’emphasis on educating pre-
natal care providers, updating clinical practice
guidelines, and periodically evaluating the per-
formance of practice guidelines.13
Women most commonly cited no percep-
tion of risk and having been tested recently as
rationales for not being tested. Most prepreg-
nancy HIV tests had been obtained relatively
close to the start of this pregnancy; those tested
within 6 months before pregnancy were more
than 1.5 times as likely not to be tested. Other
researchershavereportedasimilarassociation.16
The US Public Health Service 1995 guidelines
specify that all women be offered testing re-
gardless of risk behavior or prior tests.12 These
guidelines freecliniciansandwomenfromhav-
ing to judge whether their assessment of risk is
accurate or how recent a test is adequate.
Some women may have good reasons for
not being tested, such as fear of adverse con-
sequences or not being psychologically pre-
pared. However, few women in our study gave
such reasons. Others also have reported that
these reasons were uncommon.16,20,25,29 It is im-
portant to elicit such concerns from women,
and when voiced, they should signal the need
for more counseling or psychological support
rather than simply a deferral of testing.
Since this study was conducted, recom-
mendations for treatment to prevent perinatal
transmission of HIV have been expanded to
include treatment of women with advanced
disease, treatment during labor and delivery
even when prenatal antiretroviral therapy was
not given, and treatment of infants whose moth-
ers received no antiretroviral therapy during
the prenatal period or during labor and deliv-
ery.31 The effect on current testing practices of
this expansion, other advances in therapeutics
and prevention measures,3–11 and changes in
policies is unknown. One report showed that
testing between 1995 and 1998 remained sta-
ble in public clinics but increased 29% in pri-
vate clinics.32 In New York State, where HIV
testing of newborns became mandatory in
1996, prenatal testing increased 12% by 1997.33
A strength of this study is its sample of
parturient women, representing a wide mix of
geography with a range of HIV prevalence.
Because we sampled hospital births, women
receiving care under all prenatal care settings
participated, regardless of when they entered
prenatal care. By conducting postpartum in-
terviews, we assessed testing for the entire pre-
natal period.
There are some limitations to these data.
They rely on women’s recall in the immedi-
ate postpartum period. We are currently in-
vestigating a comparison of women’s recall
with documentation of testing in medical
records for a subsample of the North Carolina
women.34 One comparison of women’s reports
with clinical records found minor discrepan-
cies in test reporting.20 Another report, which
used hospital laboratory data, found larger dis-
crepancies.35 Others have noted that women
commonly assume that blood samples drawn
during prenatal care are tested for HIV.25 At a
low level of misclassification, our key find-
ings on the testing proportions would not
change appreciably, although the analysis of
barriers to testing may be biased. The accu-
racy of women’s perception of a provider’s rec-
ommendation cannot be validated; however,
it is probably the women’s interpretation of
the recommendation that informs their deci-
sion making. Finally, the study hospitals were
all teaching facilities, most with considerable
experience caring for HIV-infected women
and children. HIV testing at the prenatal care
practices delivering at the study hospitals may
be more common than at practices delivering
at other hospitals in these states.
This study suggests that the US health care
system is falling short of the goal of universal
offering of voluntary HIV counseling and test-
ing, and it supports the need to increase HIV
testing if HIV infection is to be eliminated
among US children.13 Our data emphasize the
importance of improving private caregivers’
understanding of the importance of universal
HIV counseling and testing to implement fully
US Public Health Service guidelines. In this
era of effective interventions, providers should
routinely encourage prenatal testing during each
pregnancy, while recognizing that our society
still attaches stigma to HIV infection and that
a few women may have legitimate reasons to re-
ject testing. As a society, we should actively
seek to mitigate the stigma associated with HIV
infection, a goal that will also help prevent new
infections. Implementing the strategy of routine
universal prenatal testing would help reduce
the stigma to individuals and to communities,
as well as the unavoidable errors of basing test
recommendation on individual risk factors or
the community prevalence of infection.
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